{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-004835","form_type":"8-K/A","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.054731+00:00","generated_at":"2026-06-19T02:49:18.593562+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"C4 Therapeutics FY2022 net loss $128.2M; cash runway to end 2024","bullets":["Revenue $31.1M in FY2022, down from $45.8M in FY2021 due to Roche agreement termination.","Net loss $128.2M ($2.62/share) vs. $83.9M ($1.82/share) in FY2021; R&D spend rose to $117.8M.","Cash, equivalents and marketable securities $337.1M at Dec 31, 2022, down from $451.5M.","Phase 1 dose escalation data for CFT7455 (MM) and CFT8634 (synovial sarcoma) expected 2H 2023.","IND submission for CFT8919 (EGFR L858R) on track for 1H 2023; CFT1946 trial dosing patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-004835","json":"https://secwatch.observer/filing/0001628280-23-004835.json","markdown":"https://secwatch.observer/filing/0001628280-23-004835.md","text":"https://secwatch.observer/filing/0001628280-23-004835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023004835/0001628280-23-004835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023004835/cccc-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:49:18.593562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e47c39842fa6eaa3ab410ac6b761486eef59c419","claim":"C4 Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $31.1 million, net income $128.2 million, EPS $2.62.","evidence_excerpt":"Revenue: Total revenue for the year ended December 31, 2022 was $31.1 million, compared to $45.8 million for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023004835/0001628280-23-004835-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$31.1 million"},{"label":"Net income","value":"$128.2 million"},{"label":"EPS","value":"$2.62"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}